Wegovy weight loss pills

While injectable treatments like Mounjaro and Wegovy have dominated the conversation around medical weight loss in Ireland until now, patients should be aware that a significant shift is on the horizon. The "Wegovy pill" - an oral version of the semaglutide injection is moving through the final stages of the regulatory pipeline, and has already been approved in the US by the FDA.

The Wegovy pill contains the same active ingredient as the injection: semaglutide. It is a GLP-1 receptor agonist that mimics a natural hormone in your body to regulate appetite and slow down digestion, helping you feel fuller for longer.

While an oral version of semaglutide (Rybelsus) has been available in Ireland for years to treat type 2 diabetes, it is only licensed at doses up to 14mg. The "Wegovy pill" specifically for weight loss uses a maintenance dose of 25mg to achieve results comparable to the 2.4mg weekly injection.

Usually, you'll be considered eligible for the Wegovy pill if you meet one of the following two Body Mass Index (BMI) thresholds:

BMI of 30 or higher: This is the standard "obesity" category where medical intervention is typically recommended alongside lifestyle changes.

BMI of 27 to 29.9: You can qualify at this lower threshold if you have at least one weight-related health condition, such as: High blood pressure (hypertension), Type 2 diabetes or pre-diabetes, High cholesterol, Obstructive sleep apnoea, or Cardiovascular disease.

You should always confirm this with your doctor.

Data from the OASIS clinical trial programme has shown that the pill is remarkably effective. In the OASIS 1 trial, adults with obesity or overweight who took the 50mg daily pill lost an average of 15.1% to 17.4% of their body weight over 68 weeks.

These results essentially match the "gold standard" set by the Wegovy injection. The trials also confirmed that the safety profile is consistent across both forms; the most common side effects remain gastrointestinal (such as nausea or heart burn), which usually ease as the body adapts to the medication.

Key differences between Wegovy injection and pill

As mentioned above, as of January 2026, the Wegovy pill has already made its debut in the United States following FDA approval in late 2025. In Ireland, the timeline is slightly different due to the EU regulatory process.

• EMA Submission: Novo Nordisk submitted the high-dose oral semaglutide for approval to the European Medicines Agency (EMA) in late 2025.
• Approval Window: we expect a decision from the EMA by mid-to-late 2026. Once the EMA grants a "centralised marketing authorisation," it becomes legally available across all EU member states, including Ireland.
• HPRA & Distribution: Following EU approval, the Health Products Regulatory Authority (HPRA) in Ireland will list it on the national register. At that point, our clinical partners will be able to assess patients for its suitability.
• Status Check: Currently, you can't get the Wegovy pill in Ireland for weight loss. Be wary of any website claiming to sell "Wegovy pills" right now - they are likely either selling the lower-dose diabetes medication (Rybelsus) off-label or, potentially, counterfeit products.

It is too early to give exact pricing for the Irish market. However, in other regions where oral semaglutide is used, the cost is often comparable to the injectable version. It is important to note that, like the injection, the Wegovy pill is expected to be available via private prescription only and is not currently slated for reimbursement under the Long-Term Illness (LTI) or Drug Payment Scheme (DPS) for weight loss in Ireland.

To stay updated on the legal status of medications in Ireland, we recommend following these official bodies:

• EMA: Semaglutide (Wegovy) Authorisation Details
• HPRA: Search the Irish Register of Medicines